Quarterly Result27 May 2026, 04:31 pm
Concord Drugs Approves FY26 Financial Results
AI Summary
Concord Drugs Ltd's board meeting on May 27, 2026, approved the standalone and consolidated financial results for the year ended March 31, 2026. The results, along with the auditor's report, are available on the company's website and the BSE Limited website. The company's total revenue increased from ₹4,525.91 lakhs to ₹7,877.13 lakhs and profit after tax increased from ₹33.62 lakhs to ₹105.50 lakhs.
Key Highlights
- Concord Drugs approved financial results for the year ended March 31, 2026.
- Total assets increased to ₹7,488.76 lakhs as of March 31, 2026.
- Revenue from operations increased to ₹7,873.68 lakhs for FY26.
- Profit after tax stood at ₹105.50 lakhs for the period ended March 31, 2026.
- Basic earnings per share increased to ₹0.95 for FY26.
Price Impact
More from CONCORD
More in Quarterly Result